KSQ Therapeutics is a Cambridge-based biotech company that uses CRISPR functional genomics to discover and develop novel cancer immunotherapies. The company's platform combines CRISPR screening with machine learning to identify new therapeutic targets in oncology. KSQ focuses on developing treatments that enhance the immune system's ability to fight cancer by targeting previously undruggable pathways.
KSQ Therapeutics has received investment from 1 venture capital firm.
A biotechnology company developing cancer immunotherapies using CRISPR-based functional genomics to identify novel drug targets.
KSQ Therapeutics has received investment from Atlas Venture. These venture capital firms and investors provide both capital and strategic support.
KSQ Therapeutics has raised $63M in total funding, with their most recent round being a Series A. The company operates in the Biotech sector.
KSQ Therapeutics was founded in 2018 and is headquartered in Cambridge, MA.
KSQ Therapeutics operates in the Biotech sector. A biotechnology company developing cancer immunotherapies using CRISPR-based functional genomics to identify novel drug targets.
